MetaCap

eXoZymes (EXOZ) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pelthos Therapeutics (PTHS) has outperformed eXoZymes (EXOZ) over the past year, losing 74.9% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $25.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EXOZ-81.84%PTHS-74.88%
+27%-30%-87%
Nov 21, 20251 yearNov 20, 2026
EXOZ-73.88%PTHS+1.11%
+471%+186%-100%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EXOZ versus PTHS key metrics
MetricEXOZPTHS
Share price$2.91$6.38
Market cap$27.42M$25.08M
1-day change-14.05%-8.73%
YTD return-73.35%-79.42%
1-year return-81.84%-74.88%
EPS (TTM)$-1.16$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.80M
Net income (latest FY)$-9.16M$-43.32M
Gross margin—76.25%
Operating margin—-193.09%
Net margin—-257.93%
52-week high$16.16$31.62
52-week low$2.81$6.02
Distance from 52-week high-82.02%-79.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside—+732.92%
Average volume10.14K54.38K
Shares outstanding9.44M3.93M
Employees3292
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About eXoZymes

EXOZ stock →

eXoZymes, Inc. operates as a development stage biotechnology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

EXOZ vs PTHS FAQ

Which is bigger, eXoZymes or Pelthos Therapeutics?

eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $25.08M for Pelthos Therapeutics (PTHS).

Which stock has performed better over the past year, EXOZ or PTHS?

PTHS returned -74.88% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.

Are eXoZymes and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons